Pfizer said on Thursday its hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain ...

The RABBIT registry is supported by a joint, unconditional grant from AbbVie, Alfasigma, Amgen, Biocon, Bristol Myers Squibb, ...

From drug trials to mechanistic insights, EULAR 2025 delivers wide-ranging data that may inform tomorrow’s standards in ...

Myocarditis, when the heart muscle gets inflamed, can make it harder for the heart to pump blood possibly causing chest pain, ...

U.S. health officials have expanded warnings about a rare heart side effect associated with the two leading COVID-19 vaccines ...

The FDA has updated labels on the top two COVID-19 vaccines to warn of a rare heart side effect, mostly seen in young men.

Elinzanetant is the first neurokinin-targeted therapy to demonstrate efficacy in reducing vasomotor symptoms (VMS)” — ...

Robert F. Kennedy Jr. had fired all 17 members of a key vaccine panel. Now his new panel recommended a new infant RSV vaccine ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment ...

AstraZeneca (NASDAQ: AZN) and Pfizer (NYSE: PFE) -- along with one biotech stock, Exelixis (NASDAQ: EXEL). (AstraZeneca): ...

On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for ...